Search AMCP NewsBreaks
The Office of the National Coordinator for Health Information Technology (ONC)
issued a final rule on Health Data, Technology, and Interoperability: Certification
Program Updates, Algorithm Transparency, and Information Sharing (Final Rule),
which is scheduled to be published in the Federal Register on Jan. 9, 2024.
AMCP Regulatory NewsBREAK: CMS Issues Letter to Plans and Pharmacy Benefit Managers
• On Nov. 6, 2023, the Centers for Medicare and Medicaid Services (CMS) issued a
memorandum titled Application of Pharmacy Price Concessions to the Negotiated
Price at the Point of Sale Beginning Jan. 1, 2024 (Memo).
Due to the COVID-19 PHE, flexibilities were implemented to prevent lapses in
patient care by allowing the prescribing of schedule II-V controlled medications via
audio-video telemedicine encounters – including schedule III-V narcotic controlled
medications approved by the Food and Drug Administration (FDA) for
maintenance and withdrawal management of opioid use disorder – even when the
prescribing practitioner had not conducted an in-person medical evaluation of the
patient.
Due to the COVID-19 PHE, flexibilities were implemented to prevent lapses in
patient care by allowing the prescribing of schedule II-V controlled medications via
audio-video telemedicine encounters – including schedule III-V narcotic controlled
medications approved by the Food and Drug Administration (FDA) for
maintenance and withdrawal management of opioid use disorder – even when the
prescribing practitioner had not conducted an in-person medical evaluation of the
patient.
On August 29, the Centers for Medicare & Medicaid Services (CMS) announced
the first 10 Part D drugs selected for negotiation under the Medicare Drug Price
Negotiation Program. The negotiation process for these drugs will take place
during 2023 and 2024, and maximum fair prices will be applicable starting in 2026.
